Patients eligible for PEGASUS in the ACTION Registry–GWTG characteristics by the use of a P2Y12 inhibitor at 1, 2 and 3 years post-MI
| Characteristics |
On P2Y12 at 1 year post-MI (n=23 042) |
On P2Y12 at 2 years post-MI (n=9661) |
On P2Y12 at 3 years post-MI (n=5246) | p Value |
| Patient demographics | ||||
| Age, mean (SD) | 69.3 (9.0) | 69.3 (9.1) | 69.1 (8.9) | 0.53 |
| Men, n (%) | 14 165 (61.5) | 5890 (61.0) | 3194 (60.9) | 0.57 |
| Race, n (%) | ||||
| White | 20 562 (89.2) | 8527 (88.3) | 4639 (88.4) | 0.02 |
| African-American | 1858 (8.1) | 848 (8.8) | 446 (8.5) | 0.09 |
| Asian | 390 (1.7) | 189 (2.0) | 107 (2.0) | 0.10 |
| Other | 232 (1.0) | 97 (1.0) | 54 (1.0) | 0.99 |
| Hispanic or Latino, n (%) | 1066 (4.6) | 494 (5.1) | 274 (5.2) | 0.05 |
| Insurance, n (%) | ||||
| None | 672 (2.9) | 284 (2.9) | 166 (3.2) | 0.63 |
| Private | 7069 (30.7) | 2 916 (30.2) | 1 558 (29.7) | 0.32 |
| Medicaid or Medicare | 15 127 (65.6) | 6 387 (66.1) | 3 482 (66.4) | 0.51 |
| Other | 174 (0.8) | 74 (0.8) | 40 (0.8) | 0.99 |
| Patient medical history | ||||
| Body mass index | 29.7 (10.4) | 29.9 (11.3) | 30.0 (11.2) | 0.22 |
| Diabetes, n (%) | 7497 (32.5) | 3257 (33.7) | 1759 (33.5) | 0.08 |
| Insulin therapy, n (%) | 1370 (5.9) | 590 (6.1) | 320 (6.1) | 0.82 |
| Hypertension, n (%) | 17 196 (74.6) | 7455 (77.2) | 4040 (77.0) | <0.001 |
| Dyslipidaemia, n (%) | 11 941 (51.8) | 5117 (53.0) | 2763 (52.7) | 0.13 |
| Current/recent smoker, n (%) | 5948 (25.8) | 2588 (26.8) | 1445 (27.5) | 0.02 |
| Cerebrovascular disease, n (%) | 882 (3.8) | 399 (4.1) | 214 (4.1) | 0.38 |
| Peripheral arterial disease, n (%) | 1465 (6.4) | 652 (6.7) | 347 (6.6) | 0.39 |
| Prior PCI, n (%) | 4336 (18.8) | 1935 (20.0) | 1045 (19.9) | 0.02 |
| Prior CABG, n (%) | 58 (0.3) | 26 (0.3) | 12 (0.2) | 0.89 |
| Prior MI, n (%) | 3807 (16.5) | 1733 (17.9) | 947 (18.1) | 0.001 |
| Prior heart failure, n (%) | 996 (4.3) | 439 (4.5) | 213 (4.1) | 0.37 |
| Chronic kidney disease, n (%) | ||||
| Stage 1 or 2 | 16 761 (72.7) | 6988 (72.3) | 3855 (73.5) | 0.32 |
| ≥Stage 3 | 6075 (26.4) | 2578 (26.7) | 1346 (25.7) | 0.40 |
| Anaemia, n (%) | 4115 (17.9) | 1786 (18.5) | 956 (18.2) | 0.38 |
| Chronic lung disease, n (%) | 2143 (9.3) | 886 (9.2) | 459 (8.7) | 0.46 |
| MI characteristics and management | ||||
| Presentation, n (%) | ||||
| STEMI | 11 146 (48.4) | 4661 (48.2) | 2542 (48.5) | 0.96 |
| NSTEMI | 11 896 (51.6) | 5000 (51.8) | 2704 (51.5) | 0.96 |
| PCI indication, n (%) | 19 852 (86.2) | 8102 (83.9) | 4379 (83.5) | <0.001 |
| DES | 15 085 (65.5) | 6112 (63.3) | 3280 (62.5) | <0.001 |
| BMS | 3872 (16.8) | 1564 (16.2) | 844 (16.1) | 0.25 |
| CABG | 949 (4.1) | 471 (4.9) | 268 (5.1) | <0.001 |
| Bleeding Risk Score, n (%) | ||||
| Very low | 3529 (15.6) | 1404 (14.8) | 749 (14.5) | 0.06 |
| Low | 12 336 (54.4) | 5170 (54.4) | 2852 (55.1) | 0.53 |
| Moderate | 6226 (27.5) | 2693 (28.3) | 1438 (27.8) | 0.28 |
| High | 546 (2.4) | 214 (2.3) | 122 (2.4) | 0.70 |
| Very high | 43 (0.2) | 24 (0.3) | 11 (0.2) | 0.53 |
ACTION Registry–GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines; ARB, angiotensin II receptor blocker; BMS, bare-metal stent; CABG, coronary artery bypass grating; DES, drug-eluting stent; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI.